Sokal Risk Score Is Superior to Hasford and EUTOS in Determining Survival Outcomes for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

被引：0
|
作者：
Jiang, Brian Gabriel [1 ]
Kim, Dong-Wook [2 ]
Shih, Lee-Yung [3 ]
Chuah, Charles [4 ,5 ]
Than, Hein [4 ]
Kuo, Ming-Chung [6 ,7 ]
Li, HuiHua [8 ]
Allen, John Carson, Jr. [9 ]
See, Lionel K. Y. [10 ]
Yap, Bernard K. C. [10 ]
Goh, Yeow-Tee [4 ,10 ]
机构：
[1] Duke Univ, Sch Med, Durham, NC USA
[2] St Marys Hosp, Dept Haematol, Seoul, South Korea
[3] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp Linkou, Dept Hematol Oncol, Taipei, Taiwan
[4] Singapore Gen Hosp, Dept Hematol, Singapore, Singapore
[5] Duke NUS Grad Med Sch, Canc & Stem Cell Biol Signature Res Program, Singapore, Singapore
[6] Chang Gung Mem Hosp Linkou, Taoyuan, Taiwan
[7] Chang Gung Univ, Taoyuan, Taiwan
[8] Hlth Serv Res, Singapore, Singapore
[9] Duke NUS Grad Med Sch, Ctr Quantitat Med, Singapore, Singapore
[10] Duke NUS Grad Med Sch, Singapore, Singapore
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia
    Jabbour, Elias
    Haddad, Fadi G.
    Sasaki, Koji
    Carter, Bing Z.
    Alvarado, Yesid
    Nasnas, Cedric
    Nasr, Lewis
    Masarova, Lucia
    Daver, Naval
    Pemmaraju, Naveen
    Short, Nicholas J.
    Skinner, Jeffrey
    Kadia, Tapan
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Issa, Ghayas C.
    Andreeff, Michael
    Kantarjian, Hagop
    [J]. CANCER, 2024, 130 (15) : 2652 - 2659
  • [42] Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
    Noriyoshi Iriyama
    Kei-Ji Sugimoto
    Eriko Sato
    Tomoiku Takaku
    Michihide Tokuhira
    Tomonori Nakazato
    Maho Ishikawa
    Hiroyuki Fujita
    Isao Fujioka
    Yuta Kimura
    Norio Asou
    Masahiro Kizaki
    Norio Komatsu
    Yoshihiro Hatta
    Tatsuya Kawaguchi
    [J]. Medical Oncology, 2018, 35
  • [43] Comparison of the Clinical Outcomes of Nilotinib and Dasatinib Therapies in Newly Diagnosed Patients in the Chronic Phase of Chronic Myeloid Leukemia: A Retrospective Analysis
    Iriyama, Noriyoshi
    Sugimoto, Kei-Ji
    Sato, Eriko
    Takaku, Tomoiku
    Tokuhira, Michihide
    Nakazato, Tomonori
    Ishikawa, Maho
    Fujita, Hiroyuki
    Kimura, Yuta
    Fujioka, Isao
    Asou, Norio
    Kizaki, Masahiro
    Komatsu, Norio
    Hatta, Yoshihiro
    Kawaguchi, Tatsuya
    [J]. BLOOD, 2018, 132
  • [44] Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
    Iriyama, Noriyoshi
    Sugimoto, Kei-Ji
    Sato, Eriko
    Takaku, Tomoiku
    Tokuhira, Michihide
    Nakazato, Tomonori
    Ishikawa, Maho
    Fujita, Hiroyuki
    Fujioka, Isao
    Kimura, Yuta
    Asou, Norio
    Kizaki, Masahiro
    Komatsu, Norio
    Hatta, Yoshihiro
    Kawaguchi, Tatsuya
    [J]. MEDICAL ONCOLOGY, 2018, 35 (11)
  • [45] Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study
    Massimo Breccia
    Patrizia Pregno
    Fausto Castagnetti
    Massimiliano Bonifacio
    Mario Tiribelli
    Antonella Gozzini
    Anna Rita Scortechini
    Luigiana Luciano
    Bruno Martino
    Fabio Stagno
    Giovanni Caocci
    Gaetano La Barba
    Michele Pizzuti
    Giovannino Ciccone
    Giuseppe Saglio
    Giorgina Specchia
    [J]. Leukemia, 2021, 35 : 1814 - 1816
  • [46] Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study
    Breccia, Massimo
    Pregno, Patrizia
    Castagnetti, Fausto
    Bonifacio, Massimiliano
    Tiribelli, Mario
    Gozzini, Antonella
    Scortechini, Anna Rita
    Luciano, Luigiana
    Martino, Bruno
    Stagno, Fabio
    Caocci, Giovanni
    La Barba, Gaetano
    Pizzuti, Michele
    Ciccone, Giovannino
    Saglio, Giuseppe
    Specchia, Giorgina
    [J]. LEUKEMIA, 2021, 35 (06) : 1814 - 1816
  • [47] Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population
    Seung-Ah Yahng
    Eun-Jung Jang
    Soo-Young Choi
    Sung-Eun Lee
    Soo-Hyun Kim
    Dong-Wook Kim
    [J]. International Journal of Hematology, 2014, 100 : 132 - 140
  • [48] Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population
    Yahng, Seung-Ah
    Jang, Eun-Jung
    Choi, Soo-Young
    Lee, Sung-Eun
    Kim, Soo-Hyun
    Kim, Dong-Wook
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 100 (02) : 132 - 140
  • [49] Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India.
    Ahmed, Rayaz
    Singh, Reema
    Kapoor, Jyotsna
    Patra, Pritish Chandra
    Agrawal, Narendra
    Bhurani, Dinesh
    Halder, Rohan
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (02): : E71 - E77
  • [50] Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Abbott, Brian L.
    [J]. CLINICAL THERAPEUTICS, 2012, 34 (02) : 272 - 281
12345